Lesson
The LUTS and BPH Framework
Lower urinary tract symptoms describe what a patient experiences. BPH is a histologic process, and neither symptom severity nor obstruction can be inferred from prostate size alone.
- BPH
- Benign prostatic enlargement
- Bladder outlet obstruction
- Storage symptoms
- Voiding symptoms
Storage, voiding, and post-micturition experiences
Transition-zone growth can add fixed resistance
Pressure and flow reveal the outlet-bladder relationship
Separate the terms
Benign prostatic hyperplasia is proliferation within the transition zone. Benign prostatic enlargement describes increased gland size. Bladder outlet obstruction is a functional pressure-flow problem. LUTS are the patient-reported storage, voiding, and post-micturition symptoms that can arise from several causes.
Trace the mechanics
Prostate and bladder-neck smooth muscle tone creates a dynamic component of resistance, while gland enlargement can create a static component. The detrusor may initially compensate with greater pressure, then develop irritability, reduced contractility, or incomplete emptying over time.
Avoid prostate tunnel vision
Urgency, nocturia, weak stream, and incomplete emptying can reflect infection, urethral stricture, bladder dysfunction, neurologic disease, diabetes, polyuria, heart failure, sleep apnea, medications, or malignancy. Symptoms should not be assigned to BPH without an evaluation.
Quick check
Lesson
Evaluation and Red-Flag Triage
A safe evaluation confirms the symptom pattern, searches for another cause, identifies complications, and establishes a baseline that can be measured after treatment.
- History
- Physical examination
- IPSS
- Urinalysis
- Red flags
History, medicines, IPSS, goals, and red flags
Physical examination and urinalysis frame the first decision
PSA context, residual, flow, imaging, or referral when useful
Build the first assessment
Current AUA guidance begins with medical and medication history, physical examination, the International Prostate Symptom Score, and urinalysis. Ask about onset, bother, storage and voiding symptoms, fluid timing, bowel function, sexual function, prior procedures, neurologic symptoms, and prescription and nonprescription drugs.
Use tests with purpose
PSA can support shared prostate-cancer screening and may act as a surrogate for gland size, but it is not a stand-alone BPH test. Digital rectal examination, post-void residual, uroflowmetry, bladder diary, renal assessment, imaging, cystoscopy, or pressure-flow testing are selected according to uncertainty, risk, and procedural planning.
Escalate urgent findings
Inability to void, fever with obstruction, gross hematuria, renal insufficiency, recurrent infection, bladder stones, severe pain, a suspicious prostate finding, or neurologic deficits require prompt evaluation. Cancer and BPH can coexist, so improvement on therapy does not replace appropriate cancer assessment.
Quick check
Lesson
Goals, Conservative Care, and Follow-Up
Treatment is driven by bother, complication risk, progression risk, and patient priorities rather than by gland size or age alone.
- Watchful waiting
- Lifestyle
- Medication review
- Shared decision
- Follow-up
Name the symptom and quality-of-life target
Enlargement, retention, renal injury, infection, stones, and bleeding
Speed, sexual function, burden, durability, and procedures
Choose observation deliberately
Minimally bothered patients without complications can use watchful waiting with education and reassessment. Fluid timing, evening alcohol or caffeine reduction, double voiding, constipation management, and review of contributing drugs can improve symptoms without creating new medication burden.
Set a measurable target
Document baseline IPSS, the symptom that matters most, quality-of-life effect, and any objective risk marker. A rapid symptom drug, a slow disease-modifying drug, and a procedure answer different clinical questions.
Reassess rather than renew automatically
AUA guidance supports reassessment about 4 to 12 weeks after starting medical therapy, with earlier review for adverse effects. Repeat IPSS and review adherence and tolerability. Post-void residual or uroflowmetry can be added when response is incomplete or diagnostic uncertainty remains.
Quick check
Lesson
Alpha-1 Blockers
Alpha-1 blockade relaxes smooth muscle in the prostate and bladder neck, producing relatively rapid symptom relief without shrinking the gland or preventing long-term progression.
- Tamsulosin
- Alfuzosin
- Silodosin
- Doxazosin
- Terazosin
Reduce smooth muscle contraction in prostate and bladder neck
Improvement begins sooner than with gland modification
Balance orthostasis, ejaculation, interactions, and cataract plans
Target dynamic resistance
Tamsulosin, alfuzosin, silodosin, doxazosin, and terazosin improve storage and voiding symptoms. Uroselective products generally create less systemic blood-pressure lowering, while doxazosin and terazosin require low starting doses and titration because first-dose hypotension and syncope can occur.
Use the exact product
Tamsulosin is commonly started at 0.4 mg once daily after the same meal. Alfuzosin extended release is 10 mg once daily immediately after the same meal. Silodosin is 8 mg once daily with food, with renal adjustment. Doxazosin and terazosin use product-specific titration. Extended-release tablets must not be substituted as if they were immediate release.
Counsel for class-specific harm
Review dizziness, falls, orthostasis, syncope, ejaculation changes, priapism, CYP3A4 interactions, and additive hypotension. Ask about cataracts and planned surgery because prior or current exposure can contribute to intraoperative floppy iris syndrome. The ophthalmology team needs the medication history even if the drug was stopped.
Quick check
Lesson
5-Alpha-Reductase Inhibitors
Finasteride and dutasteride lower intraprostatic dihydrotestosterone, slowly reduce gland volume, and reduce progression risk when true enlargement is present.
- Finasteride
- Dutasteride
- DHT
- Prostate volume
- PSA
5-alpha-reductase converts testosterone within prostate tissue
DHT supports androgen-driven gland growth
Lower DHT, reduce volume, and reduce progression risk in enlargement
Change androgen exposure
Finasteride primarily inhibits type 2 5-alpha-reductase, while dutasteride inhibits types 1 and 2. Reduced conversion of testosterone to dihydrotestosterone decreases the androgenic growth signal and can reduce prostate volume over months.
Select the right phenotype
AUA guidance supports 5-alpha-reductase inhibitor therapy for symptom improvement when enlargement is shown by prostate volume above 30 g, PSA above 1.5 ng/mL as a size surrogate, or palpable enlargement. These drugs are not useful rapid-relief agents for a small prostate without progression risk.
Interpret PSA and counsel precisely
Finasteride 5 mg and dutasteride 0.5 mg are taken once daily. PSA commonly falls about 50 percent after sustained therapy, so a new baseline and trend are required. Evaluate a confirmed rise from the treated nadir. Review libido, erection, ejaculation, breast effects, fertility considerations, mood symptoms, fetal risk from damaged dosage forms, and dutasteride blood-donation restrictions.
Quick check
Lesson
Tadalafil for LUTS
Tadalafil 5 mg once daily can improve lower urinary tract symptoms with or without erectile dysfunction, but it does not establish that obstruction has resolved or that progression risk has fallen.
- PDE5
- Nitric oxide
- cGMP
- Erectile dysfunction
- Nitrates
Guanylate cyclase produces cyclic GMP
Tadalafil slows cyclic GMP breakdown
Daily therapy can improve LUTS and erectile function
Follow the signal
PDE5 inhibition preserves cyclic GMP signaling and reduces smooth-muscle tone in the lower urinary tract. The precise mechanism of symptom benefit is multifactorial. Tadalafil can improve IPSS and erectile function, while peak urinary flow and prostate size may change little.
Dose the daily indication
The labeled BPH dose is 5 mg once daily at approximately the same time, with or without food. For creatinine clearance 30 to 50 mL/min, start at 2.5 mg and consider 5 mg based on response. Once-daily BPH use is not recommended below 30 mL/min or during hemodialysis.
Prevent vascular harm
Organic nitrates and guanylate-cyclase stimulators are contraindicated. Review alpha blockers, antihypertensives, alcohol, strong CYP3A4 inhibitors, cardiovascular fitness for sexual activity, hypotension, priapism, sudden hearing change, and sudden vision change. Finasteride plus tadalafil initiation is limited to 26 weeks under current labeling.
Quick check
Lesson
Persistent Storage Symptoms
Urgency, frequency, and urge incontinence may persist after outlet-directed therapy and can require a bladder-directed strategy after retention risk is assessed.
- Antimuscarinic
- Beta-3 agonist
- Post-void residual
- Urgency
- Combination therapy
Separate storage symptoms from polyuria and nocturnal production
Estimate retention risk and detrusor performance
Choose bladder therapy using cognition, pressure, interactions, and organ function
Define the residual problem
A frequency-volume chart, fluid and diuretic review, urinalysis, glycemic assessment, sleep history, and symptom timing can separate bladder storage symptoms from polyuria or nocturnal urine production. Persistent symptoms do not automatically mean the alpha blocker failed.
Select bladder-directed therapy
An antimuscarinic can reduce urgency by limiting muscarinic detrusor signaling. A beta-3 agonist can relax detrusor muscle during storage. Either may be used alone in selected patients or added to an alpha blocker when storage symptoms remain important.
Protect emptying and cognition
Review post-void residual, weak flow, retention history, constipation, glaucoma, cognitive vulnerability, blood pressure, renal and hepatic function, and interactions. Current EAU guidance advises against alpha-blocker plus antimuscarinic therapy when post-void residual exceeds 150 mL. Product-specific labeling still governs final use.
Quick check
Lesson
Acute Urinary Retention
Acute inability to void is a urologic problem that requires decompression, cause assessment, and a deliberate plan for catheter removal rather than a routine outpatient dose increase.
- Catheterization
- Alpha blocker
- Trial without catheter
- Precipitating drugs
- Recurrence
Protect comfort, bladder function, and kidney function
Review obstruction, infection, constipation, anesthesia, and medicines
Use alpha blockade, adequate time, and recurrence counseling
Recognize and decompress
Painful inability to void, suprapubic distention, overflow, agitation, or kidney injury can indicate acute retention. Prompt bladder drainage and assessment are required. Severe infection, hematuria, trauma, neurologic deficit, or difficult catheterization changes the emergency pathway.
Find the precipitant
Progressive outlet obstruction can combine with anesthesia, constipation, infection, immobility, antimuscarinic burden, sympathomimetics, opioids, or other medicines. Medication reconciliation can reveal a reversible contributor but should not delay decompression.
Plan the voiding trial
AUA guidance supports an oral alpha blocker before a trial without catheter for BPH-related acute retention. The patient should receive at least three days of therapy before the trial and should understand that recurrence remains possible even after successful voiding.
Quick check
Lesson
When Medication Is Not Enough
Procedural care is not a treatment failure. It is the correct pathway when complications, anatomy, medication burden, or patient goals make a durable intervention preferable.
- Surgery
- Minimally invasive therapy
- Prostate anatomy
- Ejaculation
- Durability
Retention, renal injury, infection, stones, bleeding, or refractory symptoms
Median lobe, gland volume, and outlet anatomy constrain options
Compare anesthesia, bleeding, catheter time, ejaculation, and retreatment
Know the strong indications
Renal insufficiency from BPH, refractory retention, recurrent infection, recurrent bladder stones, recurrent gross hematuria attributed to BPH, and symptoms refractory to or incompatible with other therapies are common reasons for procedural management.
Complete the procedural workup
Prostate size and shape, intravesical protrusion or median lobe, post-void residual, uroflowmetry, and diagnostic uncertainty influence planning. Cystoscopy, imaging, or pressure-flow testing is selected when the information will change the intervention.
Compare outcomes that matter
Transurethral resection, laser enucleation or vaporization, water-vapor therapy, prostatic urethral lift, temporary implantable devices, robotic waterjet treatment, and simple prostatectomy have different anatomy limits, durability, bleeding, anesthesia, catheter, ejaculation, and retreatment profiles. Shared decisions should compare those tradeoffs, not only the procedure name.
Quick check
Lesson
Longitudinal Medication Management
A complete plan tracks symptoms, safety, progression, prostate-cancer assessment, adherence, and the point at which another strategy becomes better than continued prescribing.
- Response
- Adherence
- PSA trend
- Adverse effects
- Escalation
Repeat symptoms and the patient-prioritized goal
Track hemodynamics, sexual effects, retention, interactions, and PSA context
Reconsider diagnosis, adherence, mechanism, and procedural care
Measure benefit
Repeat the same symptom tool, ask about the patient-prioritized symptom, review nocturia and bladder diary patterns, and assess quality of life. Objective measures such as residual volume and flow are added when risk or uncertainty warrants them.
Measure harm
For alpha blockers, assess dizziness, blood pressure, falls, ejaculation, and cataract planning. For 5-alpha-reductase inhibitors, assess sexual and breast effects, mood, adherence, and PSA trajectory. For tadalafil, assess hemodynamics, interacting drugs, vision or hearing symptoms, and priapism. Bladder agents require retention and product-specific monitoring.
Reconsider the diagnosis and strategy
No response can reflect nonadherence, an incorrect diagnosis, insufficient duration, untreated storage disease, poor detrusor contractility, urethral disease, cancer, or anatomy better suited to a procedure. Avoid stacking drugs indefinitely without a new assessment.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 104 question bank.
Each attempt draws a fresh set and rearranges the answer choices.